Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

j m mcgill ltd - dalteparin sodium - solution for injection - 25000unit/1ml

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

j m mcgill ltd - dalteparin sodium - solution for injection - 25000unit/1ml

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

j m mcgill ltd - dalteparin sodium - solution for injection - 12500unit/1ml

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

j m mcgill ltd - dalteparin sodium - solution for injection - 25000unit/1ml

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

j m mcgill ltd - dalteparin sodium - solution for injection - 25000unit/1ml

Izrael - angličtina - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - dalteparin sodium - solution for injection - dalteparin sodium 5000 iu / 0.2 ml - dalteparin - dalteparin - prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. treatment of acute deep venous thrombosis and/or pulmonary embolism.unstable coronary artery disease. thromboprophylaxis in conjunction with surgery. prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections.cancer patients : treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.

Izrael - angličtina - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - dalteparin sodium - solution for injection - dalteparin sodium 2500 iu / 0.2 ml - dalteparin - dalteparin - prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. treatment of acute deep venous thrombosis and/or pulmonary embolism. unstable coronary artery disease. thromboprophylaxis in conjunction with surgery. prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections.cancer patients : treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.

Izrael - angličtina - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - dalteparin sodium - solution for injection - dalteparin sodium 2500 iu/ml - dalteparin - dalteparin - prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. treatment of acute deep venous thrombosis and/or pulmonary embolism. unstable coronary artery disease. thromboprophylaxis in conjunction with surgery. prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections. cancer patients : treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - dalteparin sodium 10000 iu/ml - solution for injection - 10000 iu/ml - active: dalteparin sodium 10000 iu/ml excipient: sodium chloride water for injection - · for the prevention of clotting in the extracorporeal system during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - dalteparin sodium 12500 iu/ml - solution for injection - 12500 iu/ml - active: dalteparin sodium 12500 iu/ml excipient: water for injection - · for the prevention of clotting in the extracorporeal system during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency